Emerging Therapeutic Targets of Sepsis-Associated Acute Kidney Injury

Seminars in Nephrology

Volumn 35, Issue 1, 2015, Pages 38-54

  Swaminathan, Sundararaman ^a   Rosner, Mitchell H ^a   Okusa, Mark D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cytokines; Inflammation; Septic shock; Therapeutics

Indexed keywords

ALKALINE PHOSPHATASE; CANNABINOID 2 RECEPTOR; CYTOFAB; DROTRECOGIN; ERITORAN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEME OXYGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; IRON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; REACTIVE OXYGEN METABOLITE; RECOMBINANT THROMBOMODULIN; THROMBOMODULIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; ENDOCANNABINOID; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; AUTOPHAGY; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CELL THERAPY; CONVALESCENCE; DISEASE ASSOCIATION; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; MITOCHONDRION; MOLECULAR DYNAMICS; NEPHRITIS; NEUROIMMUNOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TREATMENT PLANNING; ACUTE KIDNEY INJURY; AGONISTS; BIOLOGICAL THERAPY; COMPLICATION; FLUID THERAPY; PROCEDURES; SHOCK, SEPTIC;

ACUTE KIDNEY INJURY; ALKALINE PHOSPHATASE; ANTI-BACTERIAL AGENTS; CELL- AND TISSUE-BASED THERAPY; ENDOCANNABINOIDS; FLUID THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEUROIMMUNOMODULATION; PPAR ALPHA; SEPSIS; SHOCK, SEPTIC; THROMBOMODULIN; VASOCONSTRICTOR AGENTS;

EID: 84925258145     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.01.005     Document Type: Review

References (157)

1. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
2. Angus D.C., van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013, 369:840-851.
3. Hutchins N.A., Unsinger J., Hotchkiss R.S., Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 2014, 20:224-233.
4. Zarjou A., Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol 2011, 22:999-1006.
5. Matejovic M., Chvojka J., Radej J., Ledvinova L., Karvunidis T., Krouzecky A., et al. Sepsis and acute kidney injury are bidirectional. Contrib Nephrol 2011, 174:78-88.
6. Opal S.M., Laterre P.F., Francois B., LaRosa S.P., Angus D.C., Mira J.P., et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162.
7. Osuchowski M.F., Welch K., Siddiqui J., Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006, 177:1967-1974.
8. Abraham E., Glauser M.P., Butler T., Garbino J., Gelmont D., Laterre P.F., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997, 277:1531-1538.
9. Matsuda A., Jacob A., Wu R., Aziz M., Yang W.L., Matsutani T., et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. J Nippon Med Sch 2012, 79:4-18.
10. Hotchkiss R., Monneret G., Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013, 13:862-874.
11. Thomas L. Germs. N Engl J Med 1972, 287:553-555.
12. Rosin D.L., Okusa M.D. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 2011, 22:416-425.
13. Uematsu S., Akira S. Toll-like receptors and innate immunity. J Mol Med (Berl) 2006, 84:712-725.
14. Creagh E.M., Oneill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006, 27:352-357.
15. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
16. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
17. Peters E., Heemskerk S., Masereeuw R., Pickkers P. Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 2014, 63:1038-1048.
18. Pickkers P., Heemskerk S., Schouten J., Laterre P.F., Vincent J.L., Beishuizen A., et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012, 16:R14.
19. Li L., Okusa M.D. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006, 2:432-444.
20. Sullivan G.W., Linden J. Role of A2A adenosine receptors in inflammation. Drug Dev Res 1998, 45:103-112.
21. Day Y.-J., Huang L., McDuffie M.J., Rosin D.L., Ye H., Chen J.F., et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003, 112:883-891.
22. Li L., Huang L., Ye H., Song S.P., Bajwa A., Lee S.J., et al. Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury. J Clin Invest 2012, 122:3931-3942.
23. Sullivan G.W., Fang G., Linden J., Scheld W.M. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 2004, 189:1897-1904.
24. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997, 142:278-287.
25. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
26. Pacher P., Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Prog Lipid Res 2011, 50:193-211.
27. Klein T.W., Newton C., Friedman H. Cannabinoid receptors and the cytokine network. Adv Exp Med Biol 1998, 437:215-222.
28. Sardinha J., Kelly M.E., Zhou J., Lehmann C. Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm 2014, 2014:978678.
29. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Huffman J.W., et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007, 293:H2210-H2218.
30. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
31. Ramirez S.H., Hasko J., Skuba A., Fan S., Dykstra H., McCormick R., et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 2012, 32:4004-4016.
32. Tschop J., Kasten K.R., Nogueiras R., Goetzman H.S., Cave C.M., England L.G., et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 2009, 183:499-505.
33. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998, 12:1035-1044.
34. Wang K., Wan Y.J. Nuclear receptors and inflammatory diseases. Exp Biol Med 2008, 233:496-506.
35. Neve B.P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J.C., Duriez P., et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001, 103:207-212.
36. Rigamonti E., Chinetti-Gbaguidi G., Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008, 28:1050-1059.
37. Lee J.W., Bajwa P.J., Carson M.J., Jeske D.R., Cong Y., Elson C.O., et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 2007, 133:108-123.
38. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710.
39. Li S., Gokden N., Okusa M.D., Bhatt R., Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005, 289:F469-F480.
40. Nagothu K.K., Bhatt R., Kaushal G.P., Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005, 68:2680-2693.
41. Tancevski I., Nairz M., Duwensee K., Auer K., Schroll A., Heim C., et al. Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2. EMBO Mol Med 2014, 6:810-820.
42. Straub R.H. Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci 2004, 25:640-646.
43. Andersson U., Tracey K.J. Reflex principles of immunological homeostasis. Annu Rev Immunol 2012, 30:313-335.
44. Rosas-Ballina M., Olofsson P.S., Ochani M., Valdes-Ferrer S.I., Levine Y.A., Reardon C., et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011, 334:98-101.
45. Kim T.H., Kim S.J., Lee S.M. Stimulation of the alpha7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. J Infect Dis 2014, 209:1668-1677.
46. Chatterjee P.K., Yeboah M.M., Dowling O., Xue X., Powell S.R., Al-Abed Y., et al. Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. PLoS One 2012, 7:e35361.
47. Bonaz B., Picq C., Sinniger V., Mayol J.F., Clarencon D. Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil 2013, 25:208-221.
48. Gigliotti J.C., Huang L., Ye H., Bajwa A., Chattrabhuti K., Lee S., et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013, 24:1451-1460.
49. Gigliotti J.C., Huang L., Bajwa A., Ye H., Mace E., Hossack J.A., et al. Ultrasound modulates the splenic neuroimmune axis In attenuating acute kidney injury. J Am Soc Nephrology. 2015, (in press).
50. Martin F.A., Murphy R.P., Cummins P.M. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 2013, 304:H1585-H1597.
51. Sutton T.A., Fisher C.J., Molitoris B.A. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002, 62:1539-1549.
52. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
53. Sharfuddin A.A., Sandoval R.M., Berg D.T., McDougal G.E., Campos S.B., Phillips C.L., et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009, 20:524-534.
54. Conway E.M., Van de Wouwer M., Pollefeyt S., Jurk K., Van Aken H., De Vriese A., et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002, 196:565-577.
55. Andreux P.A., Houtkooper R.H., Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 2013, 12:465-483.
56. Opal S.M., Huber C.E. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit Care 2002, 6:125-136.
57. Wang H., Yang H., Czura C.J., Sama A.E., Tracey K.J. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001, 164:1768-1773.
58. Vincent J.L. Management of sepsis in the critically ill patient: key aspects. Expert Opin Pharmacother 2006, 7:2037-2045.
59. McCulloch E.A., Till J.E. Perspectives on the properties of stem cells. Nat Med 2005, 11:1026-1028.
60. Morigi M., Introna M., Imberti B., Corna D., Abbate M., Rota C., et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008, 26:2075-2082.
61. Herrera M.B., Bussolati B., Bruno S., Fonsato V., Romanazzi G.M., Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004, 14:1035-1041.
62. Herrera M.B., Bussolati B., Bruno S., Morando L., Mauriello-Romanazzi G., Sanavio F., et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007, 72:430-441.
63. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
64. Bi B., Schmitt R., Israilova M., Nishio H., Cantley L.G. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007, 18:2486-2496.
65. Alagesan S., Griffin M.D. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?. Curr Opin Organ Transplant 2014, 19:65-72.
66. Perico N., Casiraghi F., Introna M., Gotti E., Todeschini M., Cavinato R.A., et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422.
67. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
68. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 2007, 25:2896-2902.
69. Togel F., Zhang P., Hu Z., Westenfelder C. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 2009, 13:2109-2114.
70. Togel F., Weiss K., Yang Y., Hu Z., Zhang P., Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007, 292:F1626-F1635.
71. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20:1053-1067.
72. Luo C.J., Zhang F.J., Zhang L., Geng Y.Q., Li Q.G., Hong Q., et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014, 41:123-129.
73. Pedrazza L., Lunardelli A., Luft C., Cruz C.U., de Mesquita F.C., Bitencourt S., et al. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflamm Res 2014, 63:719-728.
74. Kinsey G.R., Sharma R., Huang L., Li L., Vergis A.L., Ye H., et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 2009, 20:1744-1753.
75. Kinsey G.R., Okusa M.D. Expanding role of T cells in acute kidney injury. Curr Opin Nephrol Hypertens 2014, 23:9-16.
76. Heuer J.G., Zhang T., Zhao J., Ding C., Cramer M., Justen K.L., et al. Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol 2005, 174:7141-7146.
77. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
78. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
79. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7:610-621.
80. Bajwa A., Huang L., Ye H., Dondeti K., Song S., Rosin D.L., et al. Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol 2012, 189:2584-2596.
81. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
82. Unsinger J., McGlynn M., Kasten K.R., Hoekzema A.S., Watanabe E., Muenzer J.T., et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010, 184:3768-3779.
83. Li W.Q., Guszczynski T., Hixon J.A., Durum S.K. Interleukin-7 regulates Bim proapoptotic activity in peripheral T-cell survival. Mol Cell Biol 2010, 30:590-600.
84. Venet F., Foray A.P., Villars-Mechin A., Malcus C., Poitevin-Later F., Lepape A., et al. IL-7 restores lymphocyte functions in septic patients. J Immunol 2012, 189:5073-5081.
85. Morre M., Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012, 7:55-68.
86. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008, 205:1701-1714.
87. Chang K., Svabek C., Vazquez-Guillamet C., Sato B., Rasche D., Wilson S., et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014, 18:R3.
88. Huang X., Chen Y., Chung C.S., Yuan Z., Monaghan S.F., Wang F., et al. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol 2014, 192:1091-1099.
89. Brahmamdam P., Inoue S., Unsinger J., Chang K.C., McDunn J.E., Hotchkiss R.S. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240.
90. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
91. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
92. Lu J., Giuntoli R.L., Omiya R., Kobayashi H., Kennedy R., Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002, 8:3877-3884.
93. Inoue S., Unsinger J., Davis C.G., Muenzer J.T., Ferguson T.A., Chang K., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010, 184:1401-1409.
94. Alves-Filho J.C., Spiller F., Cunha F.Q. Neutrophil paralysis in sepsis. Shock 2010, 34(Suppl 1):15-21.
95. Kovach M.A., Standiford T.J. The function of neutrophils in sepsis. Curr Opin Infect Dis 2012, 25:321-327.
96. Cummings C.J., Martin T.R., Frevert C.W., Quan J.M., Wong V.A., Mongovin S.M., et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999, 162:2341-2346.
97. Meisel C., Schefold J.C., Pschowski R., Baumann T., Hetzger K., Gregor J., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.
98. Hall M.W., Knatz N.L., Vetterly C., Tomarello S., Wewers M.D., Volk H.D., et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011, 37:525-532.
99. Gutteridge J.M., Halliwell B. Iron toxicity and oxygen radicals. Baillieres Best Pract Res Clin Haematol 1989, 2:195-256.
100. Saletta F., Suryo Rahmanto Y., Siafakas A.R., Richardson D.R. Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes. J Biol Chem 2011, 286:35396-35406.
101. Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol 2009, 21:63-67.
102. Drakesmith H., Prentice A.M. Hepcidin and the iron-infection axis. Science 2012, 338:768-772.
103. Figueiredo N., Chora A., Raquel H., Pejanovic N., Pereira P., Hartleben B., et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013, 39:874-884.
104. Portugal S., Carret C., Recker M., Armitage A.E., Goncalves L.A., Epiphanio S., et al. Host-mediated regulation of superinfection in malaria. Nat Med 2011, 17:732-737.
105. De Domenico I., Zhang T.Y., Koening C.L., Branch R.W., London N., Lo E., et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010, 120:2395-2405.
106. Thuma P.E., Mabeza G.F., Biemba G., Bhat G.J., McLaren C.E., Moyo V.M., et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 1998, 92:214-218.
107. Messaris E., Antonakis P.T., Memos N., Chatzigianni E., Leandros E., Konstadoulakis M.M. Deferoxamine administration in septic animals: improved survival and altered apoptotic gene expression. Int Immunopharmacol 2004, 4:455-459.
108. Nizet V., Johnson R.S. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009, 9:609-617.
109. Peyssonnaux C., Cejudo-Martin P., Doedens A., Zinkernagel A.S., Johnson R.S., Nizet V. Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol 2007, 178:7516-7519.
110. Yeh C.H., Chou W., Chu C.C., So E.C., Chang H.C., Wang J.J., et al. Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide. Shock 2011, 36:510-516.
111. Nath K.A., Haggard J.J., Croatt A.J., Grande J.P., Poss K.D., Alam J. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000, 156:1527-1535.
112. Nath K.A. Heme oxygenase-1 and acute kidney injury. Curr Opin Nephrol Hypertens 2014, 23:17-24.
113. Agarwal A., Nick H.S. Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J Am Soc Nephrol 2000, 11:965-973.
114. Ferenbach D.A., Ramdas V., Spencer N., Marson L., Anegon I., Hughes J., et al. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther 2010, 18:1706-1713.
115. Bolisetty S., Traylor A., Zarjou A., Johnson M.S., Benavides G.A., Ricart K., et al. Mitochondria-targeted heme oxygenase-1 decreases oxidative stress in renal epithelial cells. Am J Physiol Renal Physiol 2013, 305:F255-F264.
116. Poole B., Wang W., Chen Y.C., Zolty E., Falk S., Mitra A., et al. Role of heme oxygenase-1 in endotoxemic acute renal failure. Am J Physiol Renal Physiol 2005, 289:F1382-F1385.
117. Wiesel P., Patel A.P., DiFonzo N., Marria P.B., Sim C.U., Pellacani A., et al. Endotoxin-induced mortality is related to increased oxidative stress and end-organ dysfunction, not refractory hypotension, in heme oxygenase-1-deficient mice. Circulation 2000, 102:3015-3022.
118. Holthoff J.H., Wang Z., Seely K.A., Gokden N., Mayeux P.R. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 2012, 81:370-378.
119. Bajcetic M., Spasic S., Spasojevic I. Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. Shock 2014, 42:179-184.
120. Tran M., Tam D., Bardia A., Bhasin M., Rowe G.C., Kher A., et al. PGC-1alpha promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest 2011, 121:4003-4014.
121. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
122. Kashani K., Al-Khafaji A., Ardiles T., Artigas A., Bagshaw S.M., Bell M., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013, 17:R25.
123. Yang Q.H., Liu D.W., Long Y., Liu H.Z., Chai W.Z., Wang X.T. Acute renal failure during sepsis: potential role of cell cycle regulation. J Infect 2009, 58:459-464.
124. Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011, 12:222-230.
125. Lo S., Yuan S.S., Hsu C., Cheng Y.J., Chang Y.F., Hsueh H.W., et al. Lc3 over-expression improves survival and attenuates lung injury through increasing autophagosomal clearance in septic mice. Ann Surg 2013, 257:352-363.
126. Howell G.M., Gomez H., Collage R.D., Loughran P., Zhang X., Escobar D.A., et al. Augmenting autophagy to treat acute kidney injury during endotoxemia in mice. PLoS One 2013, 8:e69520.
127. Ranieri V.M., Thompson B.T., Barie P.S., Dhainaut J.F., Douglas I.S., Finfer S., et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064.
128. Savva A., Roger T. Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol 2013, 4:387.
129. Tidswell M., Tillis W., Larosa S.P., Lynn M., Wittek A.E., Kao R., et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010, 38:72-83.
130. Arad G., Levy R., Nasie I., Hillman D., Rotfogel Z., Barash U., et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 2011, 9:e1001149.
131. Bulger E.M., Maier R.V., Sperry J., Joshi M., Henry S., Moore F.A., et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg 2014, In press.
132. Guntupalli K., Dean N., Morris P.E., Bandi V., Margolis B., Rivers E., et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013, 41:706-716.
133. Vincent J.L., Ramesh M.K., Ernest D., LaRosa S.P., Pachl J., Aikawa N., et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013, 41:2069-2079.
134. Igonin A.A., Protsenko D.N., Galstyan G.M., Vlasenko A.V., Khachatryan N.N., Nekhaev I.V., et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit Care Med 2012, 40:770-777.
135. Rice T.W., Wheeler A.P., Morris P.E., Paz H.L., Russell J.A., Edens T.R., et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006, 34:2271-2281.
136. Echtenacher B., Urbaschek R., Weigl K., Freudenberg M.A., Mannel D.N. Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology 2003, 208:381-389.
137. Docke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3:678-681.
138. Shubin N.J., Chung C.S., Heffernan D.S., Irwin L.R., Monaghan S.F., Ayala A. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92:593-603.
139. Zarychanski R., Doucette S., Fergusson D., Roberts D., Houston D.S., Sharma S., et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008, 36:2973-2979.
140. Jaimes F., De La Rosa G., Morales C., Fortich F., Arango C., Aguirre D., et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009, 37:1185-1196.
141. Thomsen R.W., Hundborg H.H., Johnsen S.P., Pedersen L., Sorensen H.T., Schonheyder H.C., et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006, 34:1080-1086.
142. Yende S., Milbrandt E.B., Kellum J.A., Kong L., Delude R.L., Weissfeld L.A., et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39:1871-1878.
143. Staubach K.H., Schroder J., Stuber F., Gehrke K., Traumann E., Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998, 133:94-100.
144. Morelli A., Ertmer C., Westphal M., Rehberg S., Kampmeier T., Ligges S., et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013, 310:1683-1691.
145. Xu L., Bao H., Si Y., Wang X. Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice. Inflamm Res 2013, 62:507-514.
146. Janz D.R., Bastarache J.A., Peterson J.F., Sills G., Wickersham N., May A.K., et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med 2013, 41:784-790.
147. Alhazzani W., Jacobi J., Sindi A., Hartog C., Reinhart K., Kokkoris S., et al. The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2013, 41:1555-1564.
148. Manzanares W., Langlois P.L., Hardy G. Update on antioxidant micronutrients in the critically ill. Curr Opin Clin Nutr Metab Care 2013, 16:719-725.
149. Cynober L. Citrulline: just a biomarker or a conditionally essential amino acid and a pharmaconutrient in critically ill patients?. Crit Care 2013, 17:122.
150. Puskarich M.A., Kline J.A., Krabill V., Claremont H., Jones A.E. Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial. J Parenter Enteral Nutr 2013, 38:736-743.
151. Sherwin R.L., Garcia A.J., Bilkovski R. Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. J Emerg Med 2012, 43:7-12.
152. Moran J.L., Graham P.L., Rockliff S., Bersten A.D. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit Care 2010, 14:R134.
153. Srinivasan V., Mohamed M., Kato H. Melatonin in bacterial and viral infections with focus on sepsis: a review. Recent Pat Endocr Metab Immune Drug Discov 2012, 6:30-39.
154. Izadpanah M., Khalili H. Potential benefits of vitamin D supplementation in critically ill patients. Immunotherapy 2013, 5:843-853.
155. Manzanares W., Hardy G. Thiamine supplementation in the critically ill. Curr Opin Clin Nutr Metab Care 2011, 14:610-617.
156. Wilson J.X. Evaluation of vitamin C for adjuvant sepsis therapy. Antioxid Redox Signal 2013, 19:2129-2140.
157. Andersson U., Tracey K.J. Neural reflexes in inflammation and immunity. J Exp Med 2012, 209:1057-1068.